Login
Communauté Vinci
Extérieur
Si votre nom d'utilisateur ne se termine pas par @vinci.be ou @student.vinci.be, utilisez le formulaire ci-dessous pour accéder à votre compte de lecteur.
Titre : | Fractionated Stereotactic Radiation Therapy for Pituitary Adenomas: An alternative escalating protocol of hypofractionated stereotactic radiotherapy delivering 35Gy in 5 fractions (2022) |
Auteurs : | S. Sumodhee ; V. Atallah ; R. Kinj ; J. Doyen ; B. LHomel ; P. Gillon ; P. Paquis ; F. Almairac ; S. Hieronimus ; R. Schiappa ; J.-L. Sadoul ; D. Sumodhee ; N. Pontikos ; Q. Richier ; Jean-Michel Hannoun-Lévi ; C. Scouarnec ; N. Chevalier ; P.-Y. Bondiau |
Type de document : | Article |
Dans : | Cancer/Radiothérapie (vol. 26, no. 4, Juin 2022) |
Article en page(s) : | p. 557-562 |
Note générale : | https://doi-org.ezproxy.vinci.be/10.1016/j.canrad.2021.08.021 |
Langues: | Anglais |
Descripteurs : |
HE Vinci Dose de radiation ; Radiochirurgie ; Système endocrinien ; Tumeurs de l'hypophyse |
Mots-clés: | Escalade de dose |
Résumé : | Purpose Evaluate efficacy and toxicity of hypofractionated stereotactic radiotherapy (HSRT) for patients treated for pituitary adenoma (PA) with an alternative HSRT escalating protocol delivering 35Gy in 5 fractions. Material and methods From June 2007 to March 2017, 29 patients with pituitary adenoma were treated in Antoine Lacassagne Cancer Centre with an alternative HSRT protocol. Prescribed dose was 35Gy in 5 fractions of 7Gy. Radiographic responses were assessed by annual MRI. Hormone blood samples were evaluated each year after HSRT. Results A total of 29 patients aged between 23 and 86 years (median 54 years) were included. Twelve patients received HSRT for recurrent cases and 12 received postoperative adjuvant HSRT, 5 patients did not have surgery. After a median follow-up period of 47 months local control rate was 96%. One patient presented an out-field tumor regrowth 73 months after HSRT. The majority of PA were endocrine-active (18 patients, 62%). After HSRT, 8 patients (44%) presented complete response on initial secretion, 4 patients (23%) presented partial response on initial secretion. Four patients (14%) presented grade 2 or more acute radiation toxicities. One grade 4 visual disorder was observed for one patient. Conclusions HSRT delivering 35Gy in 5 fractions represents a feasible treatment and shows promising results to reduce hormonal overproduction and to improve local control in PA. |
Disponible en ligne : | Oui |
En ligne : | https://login.ezproxy.vinci.be/login?url=https://www.sciencedirect.com/science/article/pii/S1278321821002584 |